Cargando…

Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome

SIMPLE SUMMARY: To understand the role of bone marrow fibrosis and its molecular changes in myelodysplastic syndrome, we retrospectively analyzed data from 814 patients. Older age, lower hemoglobin, unfavorable karyotype and higher BM blast were more often observed in patients with moderate/severe f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Youshan, Guo, Juan, Zhao, Sida, Wang, Roujia, Shi, Lei, Fang, Ying, Zhang, Zheng, Song, Luxi, Wu, Dong, Chang, Chunkang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221530/ https://www.ncbi.nlm.nih.gov/pubmed/35740649 http://dx.doi.org/10.3390/cancers14122984

Ejemplares similares

Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes
por: Zhang, Zheng, et al.
Publicado: (2022)

S100a9 deficiency accelerates MDS-associated tumor escape via PD-1/PD-L1 overexpression: S100a9 deficiency accelerates tumor escape
por: Wang, Roujia, et al.
Publicado: (2023)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway
por: Guo, Juan, et al.
Publicado: (2017)

Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway
por: Zheng, Qingqing, et al.
Publicado: (2018)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update
por: Jain, Akriti G., et al.
Publicado: (2022)

GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome
por: Zhou, Jing‐Dong, et al.
Publicado: (2016)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
por: Niparuck, Pimjai, et al.
Publicado: (2021)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
por: Cumbo, Cosimo, et al.
Publicado: (2020)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

High expression of APAF-1 elevates erythroid apoptosis in iron overload myelodysplastic syndrome
por: Gu, Shucheng, et al.
Publicado: (2013)

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Loschi, Michael, et al.
Publicado: (2022)

Downregulation of MMP1 in MDS-derived mesenchymal stromal cells reduces the capacity to restrict MDS cell proliferation
por: Zhao, Sida, et al.
Publicado: (2017)

Ribosomal protein L23 negatively regulates cellular apoptosis via the RPL23/Miz-1/c-Myc circuit in higher-risk myelodysplastic syndrome
por: Qi, Yuekun, et al.
Publicado: (2017)

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis
por: Ramos, Fernando, et al.
Publicado: (2016)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
por: Haase, Detlef, et al.
Publicado: (2019)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

IGF-IR promotes clonal cell proliferation in myelodysplastic syndromes via inhibition of the MAPK pathway
por: He, Qi, et al.
Publicado: (2020)

P700: THE MECHANISM OF SETD2 IN MESENCHYMAL STEM CELLS REGULATED UBA5 IN MDS ERYTHROID DIFFERENTIATION
por: Wang, Roujia, et al.
Publicado: (2023)

Bone marrow niches in myelodysplastic syndromes
por: Tosato, Giovanna, et al.
Publicado: (2021)

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
por: Daver, Naval G., et al.
Publicado: (2022)

Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis
por: Takahashi, Shuichiro, et al.
Publicado: (2016)

Significance of TP53 Mutational Status-Associated Signature in the Progression and Prognosis of Endometrial Carcinoma
por: Chen, Ying, et al.
Publicado: (2022)

TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
por: Patel, Shyam A., et al.
Publicado: (2022)

TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model
por: Pabst, Gabriel, et al.
Publicado: (2020)

Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells
por: Guo, Juan, et al.
Publicado: (2018)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports
por: Duarte, Fernando Barroso, et al.
Publicado: (2017)

P739: INCREASED FOXO1 EXPRESSION IS ASSOCIATED WITH BETTER PROGNOSIS IN MYELODYSPLASTIC SYNDROME PATIENTS RECEIVING DECITABINE THERAPY
por: Zhang, Zheng, et al.
Publicado: (2023)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes
por: Wang, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_krmscnasirb8dig1fccfldc9hh